3,375
Views
5
CrossRef citations to date
0
Altmetric
Psychiatrys

Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies

ORCID Icon, , , &
Pages 613-619 | Received 20 Nov 2022, Accepted 05 Feb 2023, Published online: 08 Mar 2023

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Masaki Kato, Toshiaki Kikuchi, Koichiro Watanabe, Tomiki Sumiyoshi, Yoshiya Moriguchi, Daniel Oudin Åström & Michael Cronquist Christensen. (2023) Assessing Reliability and Validity of the Oxford Depression Questionnaire (ODQ) in a Japanese Clinical Population. Neuropsychiatric Disease and Treatment 19, pages 2401-2412.
Read now

Articles from other publishers (4)

Alessandro Cuomo, Andrea Aguglia, Domenico De Berardis, Antonio Ventriglio, Camilla Gesi & Andrea Fagiolini. (2024) Individualized strategies for depression: narrative review of clinical profiles responsive to vortioxetine. Annals of General Psychiatry 23:1.
Crossref
Francesco Weiss, Bruno Pacciardi, Giulia D’Alessandro, Valerio Caruso, Icro Maremmani, Stefano Pini & Giulio Perugi. (2024) The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature. Journal of Clinical Medicine 13:2, pages 531.
Crossref
Alessandro Padovani, Angelo Antonini, Paolo Barone, Giuseppe Bellelli, Andrea Fagiolini, Luigi Ferini Strambi, Sandro Sorbi & Fabrizio Stocchi. (2023) Exploring depression in Alzheimer’s disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management. Neurological Sciences 44:12, pages 4323-4332.
Crossref
Alessandro Serretti. (2023) Anhedonia and Depressive Disorders. Clinical Psychopharmacology and Neuroscience 21:3, pages 401-409.
Crossref